阿帕替尼联合TACE对肝癌患者AFP、VEGF和CEA的影响

肝脏 ›› 2018, Vol. 23 ›› Issue (5): 426-429.

阿帕替尼联合TACE对肝癌患者AFP、VEGF和CEA的影响

黎莹, 杨冬阳, 赖晓嵘, 刘建化, 江韦韦, 马冬

510000 广州广东省人民医院、广东省医学科学院胃肠肿瘤内科

收稿日期:2017-11-23 出版日期:2018-05-31 发布日期:2020-04-28
通讯作者: 马冬

Received:2017-11-23 Online:2018-05-31 Published:2020-04-28

摘要/Abstract

摘要： 目的观察阿帕替尼联合经动脉化疗栓塞(transcatheter arterial chemoembolization, TACE)对肝癌患者甲胎蛋白(α-fetoprotein, AFP)、血管内皮生长因子(vascular endothelial growth factor, VEGF)、癌胚抗原(carcinoembryonic antigen, CEA)的影响。方法收集2014年12月至2017年1月我院收治的原发性肝癌患者106例,随机分为2个组:对照组52例和观察组54例。对照组接受TACE,观察组在TACE基础上给予阿帕替尼。结果两组患者治疗前外周血的AFP、VEGF和CEA差异无统计学意义,治疗后均有不同程度的降低,观察组降低更明显(P<0.05);与对照组比,观察组的临床获益人数较多(P<0.05)、生存时间较长(P<0.05)。结论阿帕替尼联合TACE可用于治疗肝癌,显著降低患者外周血AFP、VEGF和CEA表达。

关键词: 阿帕替尼, 经动脉化疗栓塞, 肝癌, 甲胎蛋白, 血管内皮生长因子, 癌胚抗原

黎莹, 杨冬阳, 赖晓嵘, 刘建化, 江韦韦, 马冬. 阿帕替尼联合TACE对肝癌患者AFP、VEGF和CEA的影响[J]. 肝脏, 2018, 23(5): 426-429.

参考文献

[1] Xu J, Zheng L, Chen J,et al.Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis,2017,8: e3095.
[2] Ai N, Liu W, Li ZG,et al.High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization.Oncol Lett,2017,14: 3953-3958.
[3] Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology,2017 Jul 26.[Epub ahead of print].
[4] Tak WY, Lin SM, Wang Y,et al.Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. Clin Cancer Res, 2018, 24: 73-83.
[5] Lai JP, Conley A, Knudsen BS, et al. Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma. Histopathology,2015, 67: 442-450.
[6] Huang H,Li Y,Li C,et al. A novel anti-VEGF targeting and MRI-visible smart drug delivery system for specific diagnosis and therapy of liver cancer.Macromol Biosci,2013,13: 1358-1368.
[7] Lin Y, Zhai E, Liao B, et al.Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.Oncotarget,2017,8:11990-12002.
[8] Zeng DX, Wang CG, Lei W,et al.Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget, 2017,8:66248-66253.
[9] Yin L, Wang J, Huang FC. Inhibitory effect of apatinib on HCT-116 cells and its mechanism.Nan Fang Yi Ke Da Xue Xue Bao,2017,37:367-372.
[10] Lu W, Jin XL, Yang C,et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther,2017,18: 433-438.
[11] Kou P, Zhang Y, Shao W,et al.Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget,2017,8: 20510-20515.
[12] Matloub AA, Aglan HA, Mohamed El Souda SS,et al.Influence of bioactive sulfated polysaccharide-protein complexes on hepatocarcinogenesis, angiogenesis and immunomodulatory activities. Asian Pac J Trop Med,2016,9: 1200-1211.

[1]	孙亮, 周旋, 刘桂治, 林茂锐, 李明友, 曹东林. 肝癌患者肠道微生态结构变化的特点分析[J]. 肝脏, 2020, 25(3): 267-269.
[2]	杨怀龙, 雷霆. CT全灌注成像在肝癌TACE介入术前肝储备功能评估中的价值[J]. 肝脏, 2020, 25(3): 270-272.
[3]	王雨, 许达峰, 周开伦, 武金才, 丁驿超, 古海强, 谢明微, 林明花. TLR4和肠道菌群在原发性肝癌进展中动态变化及与预后的关系[J]. 肝脏, 2020, 25(3): 273-276.
[4]	周友乾, 罗心晨, 邹喜荣, 李翠, 欧阳帆, 尹凤鸣. HBsAg阴性HBV相关原发性肝癌临床特点分析[J]. 肝脏, 2020, 25(3): 288-291.
[5]	冯文杏, 周小舟, 韩志毅, 孙新锋, 马文峰, 张卫. GALAD模型在诊断HBV相关肝细胞癌中的价值探讨[J]. 肝脏, 2020, 25(3): 291-294.
[6]	余守江, 王国兴, 马兰芳. TACE联合微波消融对原发性肝癌患者肿瘤组织灌注、免疫功能及预后的影响[J]. 肝脏, 2020, 25(3): 294-296.
[7]	李彦伟. PCR检测HBV前C/C基因启动子区变异与肝细胞癌的关系[J]. 肝脏, 2020, 25(3): 300-301.
[8]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[9]	龙云铸, 贺萧瑾, 李丹, 周娟, 周青, 谭英征. HBx介导SOCS-1基因甲基化致肝细胞癌发生的机制[J]. 肝脏, 2020, 25(2): 202-205.
[10]	刘莉, 唐世刚. 核苷类似物治疗的慢性乙型肝炎患者合并肝癌的临床特征分析[J]. 肝脏, 2020, 25(2): 172-174.
[11]	王家欢, 李震. 对比经皮射频消融术和经腹腔镜下肝切除术治疗Ⅰa期原发性肝癌的临床效果[J]. 肝脏, 2020, 25(2): 146-148.
[12]	李祥苏, 金星星, 王冬冬, 吴旭东. 血清LECT2检测对肝细胞癌诊断的意义[J]. 肝脏, 2020, 25(1): 71-72.
[13]	孙艳华, 夏瑞雪, 王宁, 鲍越. AFP-L3、AFP、GP73、ALP联合检测对原发性肝癌的诊断价值研究[J]. 肝脏, 2020, 25(1): 63-65.
[14]	郑树成, 李玉柱, 王洪峰, 张德江, 赵林. 螺旋CT引导下肿瘤组织间¹²⁵I粒子植入用于肝癌的疗效分析[J]. 肝脏, 2020, 25(1): 59-60.
[15]	张黎, 杨荣, 赵云. 原发性肝癌中血清PTN和GP73的表达及其在临床诊断中的意义[J]. 肝脏, 2020, 25(1): 56-58.